104 related articles for article (PubMed ID: 26407158)
61. TheMedical Insurance for a New Generation: another step towards universal health coverage in Mexico.
Woldenberg SC
Salud Publica Mex; 2012; 54 Suppl 1():S1-2. PubMed ID: 22965437
[No Abstract] [Full Text] [Related]
62. Did Universal Access to ARVT in Mexico Impact Suboptimal Antiretroviral Prescriptions?
Caro-Vega Y; Volkow P; Sierra-Madero J; Colchero MA; Crabtree-Ramírez B; Bautista-Arredondo S
AIDS Res Treat; 2013; 2013():170417. PubMed ID: 24396592
[TBL] [Abstract][Full Text] [Related]
63. Optimized design and experimental study of a macroscopic mirror to achieve linear amplification of optical force-induced displacement.
Gu C; Huang S; Fang F
Opt Express; 2023 Aug; 31(18):28830-28849. PubMed ID: 37710694
[TBL] [Abstract][Full Text] [Related]
64. Disparities and crisis: access to opioid medicines in Mexico.
Knaul FM
Lancet Public Health; 2021 Feb; 6(2):e83-e84. PubMed ID: 33516289
[No Abstract] [Full Text] [Related]
65. [Universal access to health: new paths of a permanent quest].
Rivera Dommarco J
Salud Publica Mex; 2019; 61(5):561-562. PubMed ID: 31661734
[No Abstract] [Full Text] [Related]
66. The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?
Angelis A; Aggarwal A; Miners A; Grieve R; Cairns J; Briggs A
J R Soc Med; 2023 Oct; 116(10):324-330. PubMed ID: 37619606
[No Abstract] [Full Text] [Related]
67. [The quest for universal health coverage: achieving social protection for all in Mexico].
Knaul FM; González-Pier E; Gómez-Dantés O; García-Junco D; Arreola-Ornelas H; Barraza-Lloréns M; Sandoval R; Caballero F; Hernández-Ávila M; Juan M; Kershenobich D; Nigenda G; Ruelas E; Sepúlveda J; Tapia R; Soberón G; Chertorivski S; Frenk J
Salud Publica Mex; 2013 Apr; 55(2):207-35. PubMed ID: 23546413
[No Abstract] [Full Text] [Related]
68. Towards Universal Health Care- A Review of the Basic Basket of Care Associated With Universal Health Care Delivery Models.
Burns RM; Dooley B; Armstrong J
Value Health; 2014 Nov; 17(7):A417-8. PubMed ID: 27201049
[No Abstract] [Full Text] [Related]
69. Medicines and universal health coverage: challenges and opportunities.
Bigdeli M; Laing R; Tomson G; Babar ZU
J Pharm Policy Pract; 2015; 8(1):8. PubMed ID: 25825675
[No Abstract] [Full Text] [Related]
70. Is the national health insurance scheme a pathway to sustained access to medicines in Nigeria?
Uguru N; Ogu U; Uguru C; Ibe O
BMC Health Serv Res; 2024 Mar; 24(1):403. PubMed ID: 38553711
[TBL] [Abstract][Full Text] [Related]
71. Trends of Antihypertensive, Antidiabetic, and Nonsteroidal Anti-Inflammatory Drugs Use among the Health Workers Cohort Study, Mexico 2004 to 2018.
Ortega-Montiel J; Montoya A; Soria-Saucedo R; Gallegos-Carrillo K; Ramírez-Palacios P; Salmerón J; Salazar-Martínez E
Adv Pharmacol Pharm Sci; 2023; 2023():5555274. PubMed ID: 38035129
[TBL] [Abstract][Full Text] [Related]
72. Cross-border utilization of cancer care by patients in the US and Mexico - a survey of Mexican oncologists.
LaPelusa M; Verduzco-Aguirre H; Diaz F; Aldaco F; Soto-Perez-de-Celis E
Global Health; 2023 Oct; 19(1):78. PubMed ID: 37891675
[TBL] [Abstract][Full Text] [Related]
73. Increase of catastrophic and impoverishing health expenditures in Mexico associated to policy changes and the COVID-19 pandemic.
Serván-Mori E; Gómez-Dantés O; Contreras D; Flamand L; Cerecero-García D; Arreola-Ornelas H; Knaul FM
J Glob Health; 2023 Oct; 13():06044. PubMed ID: 37883200
[TBL] [Abstract][Full Text] [Related]
74. The Impact of Seguro Popular on the Progression of Disabilities Among Older Adults With Chronic Degenerative Diseases in Mexico.
van Gameren E; Enciso N
Res Aging; 2023; 45(9-10):599-608. PubMed ID: 36515312
[TBL] [Abstract][Full Text] [Related]
75. A systematic review of the literature on the impact of the Seguro Popular.
Colchero MA; Gómez R; Bautista-Arredondo S
Health Res Policy Syst; 2022 Apr; 20(1):42. PubMed ID: 35436938
[TBL] [Abstract][Full Text] [Related]
76. Has Latin America achieved universal health coverage yet? Lessons from four countries.
Gilardino RE; Valanzasca P; Rifkin SB
Arch Public Health; 2022 Jan; 80(1):38. PubMed ID: 35063033
[TBL] [Abstract][Full Text] [Related]
77. Evaluating essential medicines for treating childhood cancers: availability, price and affordability study in Ghana.
Mensah KB; Mensah ABB; Bangalee V; Padayachee N; Oosthuizen F
BMC Cancer; 2021 Jun; 21(1):683. PubMed ID: 34112117
[TBL] [Abstract][Full Text] [Related]
78. Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.
Moye-Holz D; Ewen M; Dreser A; Bautista-Arredondo S; Soria-Saucedo R; van Dijk JP; Reijneveld SA; Hogerzeil HV
BMC Health Serv Res; 2020 May; 20(1):424. PubMed ID: 32410676
[TBL] [Abstract][Full Text] [Related]
79. Access to innovative cancer medicines in a middle-income country - the case of Mexico.
Moye-Holz D; Soria Saucedo R; van Dijk JP; Reijneveld SA; Hogerzeil HV
J Pharm Policy Pract; 2018; 11():25. PubMed ID: 30386627
[TBL] [Abstract][Full Text] [Related]
80. Mortality in Patients With Chronic Renal Disease Without Health Insurance in Mexico: Opportunities for a National Renal Health Policy.
Valdez-Ortiz R; Navarro-Reynoso F; Olvera-Soto MG; Martin-Alemañy G; Rodríguez-Matías A; Hernández-Arciniega CR; Cortes-Pérez M; Chávez-López E; García-Villalobos G; Hinojosa-Heredia H; Camacho-Aguirre AY; Valdez-Ortiz Á; Cantú-Quintanilla G; Gómez-Guerrero I; Reding A; Pérez-Navarro M; Obrador G; Correa-Rotter R
Kidney Int Rep; 2018 Sep; 3(5):1171-1182. PubMed ID: 30197984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
